Karolinska Development AB (publ) (KDEV.ST)
SEK 1.0
(-0.9%)
SEK 1.0
(-0.9%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -82.2 Million SEK | 36.93% |
| 2022 | -130.32 Million SEK | -257.14% |
| 2021 | 82.93 Million SEK | 11647.45% |
| 2020 | 706 Thousand SEK | -98.17% |
| 2019 | 38.55 Million SEK | -91.66% |
| 2018 | 462.46 Million SEK | 28.5% |
| 2017 | 359.87 Million SEK | -6.24% |
| 2016 | 383.83 Million SEK | 16.45% |
| 2015 | 329.61 Million SEK | 3205.08% |
| 2014 | 9.97 Million SEK | 130.97% |
| 2013 | -32.2 Million SEK | 72.49% |
| 2012 | -117.03 Million SEK | 27.47% |
| 2011 | -161.34 Million SEK | -53.19% |
| 2010 | -105.32 Million SEK | 73.27% |
| 2009 | -394.07 Million SEK | -3975.19% |
| 2008 | -9.67 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -64.65 Million SEK | 21.35% |
| 2024 Q2 | -47.12 Million SEK | 27.11% |
| 2023 Q1 | -126.63 Million SEK | 2.83% |
| 2023 Q3 | -129.73 Million SEK | -10.3% |
| 2023 Q2 | -117.61 Million SEK | 7.12% |
| 2023 Q4 | -82.2 Million SEK | 36.64% |
| 2023 FY | -82.2 Million SEK | 36.93% |
| 2022 Q3 | -117.92 Million SEK | 36.19% |
| 2022 Q4 | -130.32 Million SEK | -10.52% |
| 2022 FY | -130.32 Million SEK | -257.14% |
| 2022 Q1 | -220.27 Million SEK | -365.59% |
| 2022 Q2 | -184.8 Million SEK | 16.1% |
| 2021 Q4 | 82.93 Million SEK | 6.1% |
| 2021 FY | 82.93 Million SEK | 11647.45% |
| 2021 Q1 | 16.89 Million SEK | 2293.48% |
| 2021 Q2 | 58.89 Million SEK | 248.51% |
| 2021 Q3 | 78.17 Million SEK | 32.74% |
| 2020 Q1 | 62.18 Million SEK | 61.28% |
| 2020 Q2 | 24.95 Million SEK | -59.86% |
| 2020 Q3 | 4.23 Million SEK | -83.04% |
| 2020 Q4 | 706 Thousand SEK | -83.32% |
| 2020 FY | 706 Thousand SEK | -98.17% |
| 2019 FY | 38.55 Million SEK | -91.66% |
| 2019 Q2 | 496.14 Million SEK | 3.0% |
| 2019 Q4 | 38.55 Million SEK | -92.32% |
| 2019 Q1 | 481.67 Million SEK | 4.15% |
| 2019 Q3 | 502.18 Million SEK | 1.22% |
| 2018 Q4 | 462.46 Million SEK | 16.16% |
| 2018 FY | 462.46 Million SEK | 28.5% |
| 2018 Q2 | 392.41 Million SEK | 1.67% |
| 2018 Q3 | 398.12 Million SEK | 1.45% |
| 2018 Q1 | 385.98 Million SEK | 7.25% |
| 2017 Q3 | 358.54 Million SEK | 3.65% |
| 2017 Q4 | 359.87 Million SEK | 0.37% |
| 2017 FY | 359.87 Million SEK | -6.24% |
| 2017 Q1 | 332.85 Million SEK | -13.28% |
| 2017 Q2 | 345.92 Million SEK | 3.93% |
| 2016 FY | 383.83 Million SEK | 16.45% |
| 2016 Q1 | 350.67 Million SEK | 6.39% |
| 2016 Q2 | 361.2 Million SEK | 3.0% |
| 2016 Q4 | 383.83 Million SEK | 5.3% |
| 2016 Q3 | 364.52 Million SEK | 0.92% |
| 2015 Q3 | 288.85 Million SEK | 28.93% |
| 2015 Q1 | 177.35 Million SEK | 1678.37% |
| 2015 FY | 329.61 Million SEK | 3205.08% |
| 2015 Q4 | 329.61 Million SEK | 14.11% |
| 2015 Q2 | 224.04 Million SEK | 26.33% |
| 2014 Q4 | 9.97 Million SEK | 155.72% |
| 2014 Q2 | -29.33 Million SEK | -320.71% |
| 2014 Q1 | -6.97 Million SEK | 78.35% |
| 2014 Q3 | 3.9 Million SEK | 113.29% |
| 2014 FY | 9.97 Million SEK | 130.97% |
| 2013 Q4 | -32.2 Million SEK | 58.43% |
| 2013 Q2 | -172.97 Million SEK | 58.78% |
| 2013 Q1 | -419.58 Million SEK | -258.52% |
| 2013 FY | -32.2 Million SEK | 72.49% |
| 2013 Q3 | -77.46 Million SEK | 55.21% |
| 2012 Q2 | -168.42 Million SEK | 0.43% |
| 2012 Q1 | -169.15 Million SEK | -4.84% |
| 2012 FY | -117.03 Million SEK | 27.47% |
| 2012 Q4 | -117.03 Million SEK | 41.79% |
| 2012 Q3 | -201.04 Million SEK | -19.36% |
| 2011 FY | -161.34 Million SEK | -53.19% |
| 2011 Q4 | -161.34 Million SEK | 0.0% |
| 2010 FY | -105.32 Million SEK | 73.27% |
| 2009 FY | -394.07 Million SEK | -3975.19% |
| 2008 FY | -9.67 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Abliva AB (publ) | -57.24 Million SEK | -43.609% |
| Aptahem AB (publ) | 2.9 Million SEK | 2926.13% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -64.335% |
| BioInvent International AB (publ) | -236.3 Million SEK | 65.213% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 1622.259% |
| Cantargia AB (publ) | -139.74 Million SEK | 41.178% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -8805.959% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 57.78% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -179.761% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | -47.089% |
| Fluicell AB (publ) | -2.76 Million SEK | -2875.1% |
| Genovis AB (publ.) | -43.94 Million SEK | -87.074% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 161.022% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 75.019% |
| Mendus AB (publ) | -96.29 Million SEK | 14.634% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 1.84% |
| Kancera AB (publ) | -45.69 Million SEK | -79.905% |
| Lipum AB (publ) | -8.46 Million SEK | -871.081% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -157.469% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 254.448% |
| Nanologica AB (publ) | -9.38 Million SEK | -775.607% |
| Saniona AB (publ) | 40.44 Million SEK | 303.234% |
| Simris Alg AB (publ) | 85.07 Million SEK | 196.623% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -81.794% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 75.361% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 149.496% |
| Xintela AB (publ) | -7.8 Million SEK | -952.657% |
| Ziccum AB (publ) | -2.13 Million SEK | -3746.607% |
| Active Biotech AB (publ) | -33.2 Million SEK | -147.596% |
| CombiGene AB (publ) | -101.44 Million SEK | 18.965% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 500.79% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -64.621% |
| LIDDS AB (publ) | -13.51 Million SEK | -508.363% |
| Biovica International AB (publ) | -58.73 Million SEK | -39.949% |
| NextCell Pharma AB | -46.79 Million SEK | -75.681% |
| Amniotics AB (publ) | -5.63 Million SEK | -1359.553% |
| BioArctic AB (publ) | -606.58 Million SEK | 86.448% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -108.73% |
| Corline Biomedical AB | -17.01 Million SEK | -383.2% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | -0.141% |
| Intervacc AB (publ) | -88.16 Million SEK | 6.758% |
| AcouSort AB (publ) | -23.98 Million SEK | -242.708% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -331.28% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 36.521% |
| SynAct Pharma AB | -61.75 Million SEK | -33.103% |
| OncoZenge AB (publ) | -12.62 Million SEK | -551.002% |
| Camurus AB (publ) | -1.16 Billion SEK | 92.946% |
| 2cureX AB (publ) | -13.4 Million SEK | -513.31% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -3703.887% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 40.497% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -521.369% |
| I-Tech AB | -83.26 Million SEK | 1.273% |
| Cyxone AB (publ) | -16.67 Million SEK | -393.113% |
| Biosergen AB | -1.88 Million SEK | -4265.481% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -283.852% |
| Alzinova AB (publ) | -21.22 Million SEK | -287.27% |
| Oncopeptides AB (publ) | -66.92 Million SEK | -22.836% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 1.838% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -1486.629% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -295.335% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -2665.882% |